Will Rhind, CEO of GraniteShares, outlines his thoughts on gold and silver heading into 2026, noting that historical precedents…
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Phase 1 1 First-In-Human study designed to assess safety , tolerability , right dose for Phase…